LinkedIn Profile

Access Seres Therapeutics historical Linkedin company profile data on number of followers, employee headcount and more
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
nasdaq:mcrb 5148589 Mar 23rd, 2024 12:00AM Seres Therapeutics 22K 329.00 Open Mar 22nd, 2024 11:54PM Mar 23rd, 2024 07:03PM Seres Therapeutics is a commercial-stage company developing novel microbiome therapeutics for serious diseases. Our lead program, VOWST™, obtained U.S. FDA approval in April 2023 as the first orally administered microbiota-based therapeutic to prevent recurrence of C. difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI and is being commercialized in collaboration with Nestlé Health Science. We are evaluating SER-155 in a Phase 1b study in patients receiving allogeneic hematopoietic stem cell transplantation to reduce incidences of gastrointestinal infections, bloodstream infections, and graft-versus-host disease as well as additional preclinical stage programs targeting Infection Protection in medically compromised patients. We are also conducting research to inform further development of microbiome therapeutics for ulcerative colitis. For more information, please visit http://www.serestherapeutics.com/ . Open Biotechnology, Therapeutics, and Microbiome Open 200 Sidney Street Cambridge Massachusetts US 02139 Seres Therapeutics Health Care Pharmaceuticals & Biotechnology
nasdaq:mcrb 5148589 Mar 22nd, 2024 12:00AM Seres Therapeutics 22K 329.00 Open Mar 21st, 2024 11:44PM Mar 22nd, 2024 06:51PM Seres Therapeutics is a commercial-stage company developing novel microbiome therapeutics for serious diseases. Our lead program, VOWST™, obtained U.S. FDA approval in April 2023 as the first orally administered microbiota-based therapeutic to prevent recurrence of C. difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI and is being commercialized in collaboration with Nestlé Health Science. We are evaluating SER-155 in a Phase 1b study in patients receiving allogeneic hematopoietic stem cell transplantation to reduce incidences of gastrointestinal infections, bloodstream infections, and graft-versus-host disease as well as additional preclinical stage programs targeting Infection Protection in medically compromised patients. We are also conducting research to inform further development of microbiome therapeutics for ulcerative colitis. For more information, please visit http://www.serestherapeutics.com/ . Open Biotechnology, Therapeutics, and Microbiome Open 200 Sidney Street Cambridge Massachusetts US 02139 Seres Therapeutics Health Care Pharmaceuticals & Biotechnology
nasdaq:mcrb 5148589 Mar 21st, 2024 12:00AM Seres Therapeutics 22K 331.00 Open Mar 20th, 2024 11:57PM Mar 21st, 2024 05:35PM Seres Therapeutics is a commercial-stage company developing novel microbiome therapeutics for serious diseases. Our lead program, VOWST™, obtained U.S. FDA approval in April 2023 as the first orally administered microbiota-based therapeutic to prevent recurrence of C. difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI and is being commercialized in collaboration with Nestlé Health Science. We are evaluating SER-155 in a Phase 1b study in patients receiving allogeneic hematopoietic stem cell transplantation to reduce incidences of gastrointestinal infections, bloodstream infections, and graft-versus-host disease as well as additional preclinical stage programs targeting Infection Protection in medically compromised patients. We are also conducting research to inform further development of microbiome therapeutics for ulcerative colitis. For more information, please visit http://www.serestherapeutics.com/ . Open Biotechnology, Therapeutics, and Microbiome Open 200 Sidney Street Cambridge Massachusetts US 02139 Seres Therapeutics Health Care Pharmaceuticals & Biotechnology
nasdaq:mcrb 5148589 Mar 20th, 2024 12:00AM Seres Therapeutics 22K 331.00 Open Mar 20th, 2024 12:38AM Mar 20th, 2024 07:36PM Seres Therapeutics is a commercial-stage company developing novel microbiome therapeutics for serious diseases. Our lead program, VOWST™, obtained U.S. FDA approval in April 2023 as the first orally administered microbiota-based therapeutic to prevent recurrence of C. difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI and is being commercialized in collaboration with Nestlé Health Science. We are evaluating SER-155 in a Phase 1b study in patients receiving allogeneic hematopoietic stem cell transplantation to reduce incidences of gastrointestinal infections, bloodstream infections, and graft-versus-host disease as well as additional preclinical stage programs targeting Infection Protection in medically compromised patients. We are also conducting research to inform further development of microbiome therapeutics for ulcerative colitis. For more information, please visit http://www.serestherapeutics.com/ . Open Biotechnology, Therapeutics, and Microbiome Open 200 Sidney Street Cambridge Massachusetts US 02139 Seres Therapeutics Health Care Pharmaceuticals & Biotechnology
nasdaq:mcrb 5148589 Mar 19th, 2024 12:00AM Seres Therapeutics 22K 331.00 Open Mar 18th, 2024 11:32PM Mar 19th, 2024 06:08PM Seres Therapeutics is a commercial-stage company developing novel microbiome therapeutics for serious diseases. Our lead program, VOWST™, obtained U.S. FDA approval in April 2023 as the first orally administered microbiota-based therapeutic to prevent recurrence of C. difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI and is being commercialized in collaboration with Nestlé Health Science. We are evaluating SER-155 in a Phase 1b study in patients receiving allogeneic hematopoietic stem cell transplantation to reduce incidences of gastrointestinal infections, bloodstream infections, and graft-versus-host disease as well as additional preclinical stage programs targeting Infection Protection in medically compromised patients. We are also conducting research to inform further development of microbiome therapeutics for ulcerative colitis. For more information, please visit http://www.serestherapeutics.com/ . Open Biotechnology, Therapeutics, and Microbiome Open 200 Sidney Street Cambridge Massachusetts US 02139 Seres Therapeutics Health Care Pharmaceuticals & Biotechnology
nasdaq:mcrb 5148589 Mar 18th, 2024 12:00AM Seres Therapeutics 22K 331.00 Open Mar 17th, 2024 11:54PM Mar 18th, 2024 07:20PM Seres Therapeutics is a commercial-stage company developing novel microbiome therapeutics for serious diseases. Our lead program, VOWST™, obtained U.S. FDA approval in April 2023 as the first orally administered microbiota-based therapeutic to prevent recurrence of C. difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI and is being commercialized in collaboration with Nestlé Health Science. We are evaluating SER-155 in a Phase 1b study in patients receiving allogeneic hematopoietic stem cell transplantation to reduce incidences of gastrointestinal infections, bloodstream infections, and graft-versus-host disease as well as additional preclinical stage programs targeting Infection Protection in medically compromised patients. We are also conducting research to inform further development of microbiome therapeutics for ulcerative colitis. For more information, please visit http://www.serestherapeutics.com/ . Open Biotechnology, Therapeutics, and Microbiome Open 200 Sidney Street Cambridge Massachusetts US 02139 Seres Therapeutics Health Care Pharmaceuticals & Biotechnology
nasdaq:mcrb 5148589 Mar 16th, 2024 12:00AM Seres Therapeutics 22K 333.00 Open Mar 15th, 2024 11:24PM Mar 16th, 2024 07:08PM Seres Therapeutics is a commercial-stage company developing novel microbiome therapeutics for serious diseases. Our lead program, VOWST™, obtained U.S. FDA approval in April 2023 as the first orally administered microbiota-based therapeutic to prevent recurrence of C. difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI and is being commercialized in collaboration with Nestlé Health Science. We are evaluating SER-155 in a Phase 1b study in patients receiving allogeneic hematopoietic stem cell transplantation to reduce incidences of gastrointestinal infections, bloodstream infections, and graft-versus-host disease as well as additional preclinical stage programs targeting Infection Protection in medically compromised patients. We are also conducting research to inform further development of microbiome therapeutics for ulcerative colitis. For more information, please visit http://www.serestherapeutics.com/ . Open Biotechnology, Therapeutics, and Microbiome Open 200 Sidney Street Cambridge Massachusetts US 02139 Seres Therapeutics Health Care Pharmaceuticals & Biotechnology
nasdaq:mcrb 5148589 Mar 15th, 2024 12:00AM Seres Therapeutics 22K 335.00 Open Mar 15th, 2024 12:58AM Mar 15th, 2024 08:57AM Seres Therapeutics is a commercial-stage company developing novel microbiome therapeutics for serious diseases. Our lead program, VOWST™, obtained U.S. FDA approval in April 2023 as the first orally administered microbiota-based therapeutic to prevent recurrence of C. difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI and is being commercialized in collaboration with Nestlé Health Science. We are evaluating SER-155 in a Phase 1b study in patients receiving allogeneic hematopoietic stem cell transplantation to reduce incidences of gastrointestinal infections, bloodstream infections, and graft-versus-host disease as well as additional preclinical stage programs targeting Infection Protection in medically compromised patients. We are also conducting research to inform further development of microbiome therapeutics for ulcerative colitis. For more information, please visit http://www.serestherapeutics.com/ . Open Biotechnology, Therapeutics, and Microbiome Open 200 Sidney Street Cambridge Massachusetts US 02139 Seres Therapeutics Health Care Pharmaceuticals & Biotechnology
nasdaq:mcrb 5148589 Mar 14th, 2024 12:00AM Seres Therapeutics 22K 335.00 Open Mar 13th, 2024 11:22PM Mar 14th, 2024 12:19PM Seres Therapeutics is a commercial-stage company developing novel microbiome therapeutics for serious diseases. Our lead program, VOWST™, obtained U.S. FDA approval in April 2023 as the first orally administered microbiota-based therapeutic to prevent recurrence of C. difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI and is being commercialized in collaboration with Nestlé Health Science. We are evaluating SER-155 in a Phase 1b study in patients receiving allogeneic hematopoietic stem cell transplantation to reduce incidences of gastrointestinal infections, bloodstream infections, and graft-versus-host disease as well as additional preclinical stage programs targeting Infection Protection in medically compromised patients. We are also conducting research to inform further development of microbiome therapeutics for ulcerative colitis. For more information, please visit http://www.serestherapeutics.com/ . Open Biotechnology, Therapeutics, and Microbiome Open 200 Sidney Street Cambridge Massachusetts US 02139 Seres Therapeutics Health Care Pharmaceuticals & Biotechnology
nasdaq:mcrb 5148589 Mar 13th, 2024 12:00AM Seres Therapeutics 22K 340.00 Open Mar 12th, 2024 11:17PM Mar 13th, 2024 10:49AM Seres Therapeutics is a commercial-stage company developing novel microbiome therapeutics for serious diseases. Our lead program, VOWST™, obtained U.S. FDA approval in April 2023 as the first orally administered microbiota-based therapeutic to prevent recurrence of C. difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI and is being commercialized in collaboration with Nestlé Health Science. We are evaluating SER-155 in a Phase 1b study in patients receiving allogeneic hematopoietic stem cell transplantation to reduce incidences of gastrointestinal infections, bloodstream infections, and graft-versus-host disease as well as additional preclinical stage programs targeting Infection Protection in medically compromised patients. We are also conducting research to inform further development of microbiome therapeutics for ulcerative colitis. For more information, please visit http://www.serestherapeutics.com/ . Open Biotechnology, Therapeutics, and Microbiome Open 200 Sidney Street Cambridge Massachusetts US 02139 Seres Therapeutics Health Care Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.